Teva Pharmaceutical Industries Limited (TEVJF) Financials
TEVJF Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| March 31, 2026 | 40.0 billion | 31.9 billion |
| Dec. 31, 2025 | 40.7 billion | 32.8 billion |
| Sept. 30, 2025 | 39.9 billion | 32.6 billion |
| June 30, 2025 | 40.1 billion | 33.3 billion |
TEVJF Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| March 31, 2026 | -208.0 million | 43.0 million |
| Dec. 31, 2025 | 721.6 million | 51.0 million |
| Sept. 30, 2025 | 233.0 million | 34.0 million |
| June 30, 2025 | 131.0 million | 38.0 million |
TEVJF Net Income
No data available :(
TEVJF Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| March 31, 2026 | 3.7 billion | 14.1 billion | 280.9 million |
| Dec. 31, 2025 | 3.6 billion | 15.0 billion | 288.1 million |
| Sept. 30, 2025 | 2.2 billion | 16.8 billion | 283.0 million |
| June 30, 2025 | 2.2 billion | 16.8 billion | 296.0 million |
TEVJF Shares Outstanding
TEVJF Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| March 31, 2026 | 168.0 million | 222.0 million | 1.0 billion | 696.0 million |
| Dec. 31, 2025 | 142.0 million | 267.0 million | 1.1 billion | 753.0 million |
| Sept. 30, 2025 | 136.0 million | 255.0 million | 975.0 million | 657.0 million |
| June 30, 2025 | 96.0 million | 244.0 million | 959.0 million | 654.0 million |
TEVJF Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| March 31, 2026 | 4.0 billion | 2.0 billion |
| Dec. 31, 2025 | 4.7 billion | 2.1 billion |
| Sept. 30, 2025 | 4.5 billion | 2.2 billion |
| June 30, 2025 | 4.2 billion | 2.1 billion |
TEVJF Revenue by Segment
Graph available only for paid members. Upgrade to see it.
TEVJF
Price: $28.40
52 week price:
Payout Ratio Range:
Earnings Per Share: 1.21 USD
P/E Ratio: 30.58
Exchange: PNK
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Market Capitalization: 38.4 billion